Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

被引：0
|
作者：
Naoki Hashimoto
Atsuhito Toyomaki
Minoru Honda
Satoru Miyano
Nobuyuki Nitta
Hiroyuki Sawayama
Yasufumi Sugawara
Keiichi Uemura
Noriko Tsukamoto
Tsukasa Koyama
Ichiro Kusumi
机构：
[1] Hokkaido University Graduate School of Medicine,Department of Psychiatry
[2] Child and Adolescent Psychiatry,Department of Psychiatry
[3] Department of Psychiatry University of California,undefined
[4] Honda Memorial Hospital,undefined
[5] Teine Hospital,undefined
[6] Sapporo Hanazono Hospital,undefined
[7] San-ai Hospital,undefined
[8] Psychiatric Medical Center,undefined
[9] Sapporo City General Hospital,undefined
[10] Hakodate Watanabe Hospital,undefined
[11] Oyachi Hospital,undefined
来源：
Annals of General Psychiatry | / 14卷
关键词：
Schizophrenia; Quetiapine; Switching; Antipsychotic; Negative symptom; Cognitive impairment; Treatment resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
    Ballon, Jacob S.
    Kahn, Rene S.
    Arevalo, Christina
    Dunbar, Martin
    Mcdonnell, David
    Correll, Christoph U.
    JOURNAL OF CLINICAL PSYCHIATRY, 2025, 86 (01)
  • [42] Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial
    Chawla, Bharat
    Luxton-Andrewl, Heather
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2008, 23 (03) : 211 - 216
  • [43] Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
    Chen, Ching-Yen
    Tang, Tze-Chun
    Chen, Tzu-Ting
    Bai, Ya Mei
    Tsai, Huei-Huang
    Chen, Hou-Liang
    Huang, Chun-Jen
    Chen, Chih-Ken
    Chen, Chun-Chih
    Hsiao, Mei-Chun
    Liu, Chia-Yih
    Yeh, Hong-Shiow
    Chiu, Nan-Ying
    Hsiao, Cheng-Chen
    Chen, Cheng-Sheng
    Su, Tung-Ping
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 725 - 732
  • [44] Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
    Kanba, Shigenobu
    Murasaki, Mitsukuni
    Koyama, Tsukasa
    Takeuchi, Masahiro
    Shimizu, Yuriko
    Arita, Eri
    Kuroishi, Kentaro
    Takeuchi, Masahiro
    Kamei, Shinya
    BMC PSYCHIATRY, 2019, 19 (1)
  • [45] LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
    Ketter, Terence A.
    Sarma, Kaushik
    Silva, Robert
    Kroger, Hans
    Cucchiaro, Josephine
    Loebel, Antony
    DEPRESSION AND ANXIETY, 2016, 33 (05) : 424 - 434
  • [46] Comparative assessment of effect on psychomotor performance efficacy and adherence of levosulpiride and olanzapine in patients with schizophrenia: A parallel, open-label, prospective observational study
    Pramoda, N.
    Turankar, V. Avinash
    Thakre, Manish Namdeo
    Mahajan, Sudhir Laludeo
    Mahakalkar, Sunil
    Shetty, Ashwita Uday
    Sasi, Sandeep M.
    ANNALS OF INDIAN PSYCHIATRY, 2023, 7 (04) : 339 - 344
  • [47] A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
    Anand, Ernie
    Berggren, Lovisa
    Deix, Claudia
    Toth, Agoston
    McDonnell, David P.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1349 - 1357
  • [48] Long-term remission in schizophrenia and related psychoses with long-acting risperidone: Results obtained in an open-label study with an observation period of 18 months
    Llorca, P. -M.
    Sacchetti, E.
    Lloyd, K.
    Kissling, W.
    Medori, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (01) : 14 - 22
  • [49] Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
    George Awad
    Daisy Ng-Mak
    Krithika Rajagopalan
    Jay Hsu
    Andrei Pikalov
    Antony Loebel
    BMC Psychiatry, 16
  • [50] Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial
    Laties, Alan M.
    Flach, Allan J.
    Baldycheva, Irina
    Rak, Ihor
    Earley, Willie
    Pathak, Sanjeev
    JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (01) : 69 - 79
12345